Tempest Therapeutics, Inc. (TPST): Entry into a Material Definitive Agreement
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d107304dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 PRODUCT DEVELOPMENT AND INVESTIGATOR-INITIATED TRIAL (IIT) COLLABORATION AGREEMENT This Product Development and Investigator-Initiated Trial (IIT) Collaboration Agreement (this “Agreement”) is entered into as of July 17, 20
How this was made
The 30-second read
Why it matters
The agreement targets generating approximately 10 to 20 evaluable patient datasets per product in China and contemplates potential China rights after completion of an agreed IIT data package, subject to a separate definitive license agreement.
Market read
This is a new, primary disclosed collaboration that may improve execution capacity in China, but the excerpt lacks financial terms and clinical outcomes, limiting immediate trading impact.
What to watch
Key missing details include development fees, payment schedule, deliverable acceptance criteria, and whether the separate definitive license agreement is likely or merely contemplated.
Background
Tempest owns CAR-T product candidates and seeks China execution via a contractor capable of process transfer, manufacturing/processing, and investigator-initiated trials.
Ticker impact
Tempest Therapeutics entered a Product Development and IIT Collaboration Agreement with a China contractor to generate 10 to 20 evaluable patient datasets per product.
Near-term reaction likely limited unless investors view the agreement as materially de-risking timelines or unlocking China licensing economics; otherwise expect modest sentiment impact.
The filing is a primary disclosure of a material definitive agreement, but the excerpt provides no financial terms, milestones, or clinical results, so incremental valuation impact is uncertain.
Market effects
Reinforces ongoing outsourcing and China execution models for CAR-T developers, but provides no broader sector datapoint beyond one company’s deal.
Highlights China-based investigator-initiated trial execution and potential future China rights, relevant to China biotech CDMO/IIT ecosystems.
Limited global read-through because the agreement is China-focused and contingent on an IIT data package and a separate license agreement.
Counterpoint
Investors may discount the deal if it is primarily operational (IIT execution) without meaningful near-term economics, milestones, or guaranteed China licensing terms.
Key entities
- public_companyTempest Therapeutics, Inc.
Sponsor of the CAR-T product development and investigator-initiated trial collaboration agreement disclosed in the 8-K.
- contractorHeibei Senlang Biotechnology Co., Ltd.
China-based contractor responsible for process receipt/transfer, manufacturing or processing support, IIT execution coordination, and data delivery.
